Anti-Candida, antiproliferative and cytotoxic activities evaluation of essential o...
Pesticide activities of acetogenins of native species of Annonaceae from Brazilian...
Use of fermentation process for the development of bean protein concentrates
Full text | |
Author(s): |
Teles, Helder Lopes
;
Sordi, Renata
;
Silva, Geraldo Humberto
;
Castro-Gamboa, Ian
;
Bolzani, Vanderlan da Silva
[5]
;
Pfenning, Ludwig Heinrich
;
Abreu, Lucas Magalhães de
;
Costa-Neto, Claudio Miguel
;
Young, Maria Claudia Marx
;
Araújo, Ângela Regina
Total Authors: 10
|
Document type: | Journal article |
Source: | Phytochemistry; v. 67, n. 24, p. 2686-2690, Dec. 2006. |
Field of knowledge: | Physical Sciences and Mathematics - Chemistry |
Abstract | |
6,8-Dimethoxy-3-(2-oxo-propyl)-coumarin (1) and 2,4-dihydroxy-6-[(1E,3E)-penta-1, 3-dienyl]-benzaldehyde (2), in addition to the known compound periconicin B (3), were isolated from the ethyl acetate extract of Periconia atropurpurea, an endophytic fungus obtained from the leaves of Xylopia aromatica, a native plant of the Brazilian Cerrado. Their chemical structures were assigned based on analyses of MS, 1D and 2D-NMR spectroscopic experiments. Biological analyses were performed using two mammalian cell lines, human cervix carcinoma (HeLa) and Chinese hamster ovary (CHO). The results showed that compound 1 had no effect when compared to the control group, which was treated with the vehicle (DMSO). Compound 2 was able to induce a slight increase in cell proliferation of HeLa (37% of increase) and CHO (38% of increase) cell lines. Analysis of compound 3 showed that it has potent cytotoxic activity against both cell lines, with an IC50 of 8.0 ÊM. Biological analyses using the phytopathogenic fungi Cladosporium sphaerospermum and C. cladosporioides revealed that also 2 showed potent antifungal activity compared to nystatin. (AU) | |
FAPESP's process: | 03/02176-7 - Conservation and sustainable use of the diversity from Cerrado and Atlantic Forest: chemical diversity and prospecting for potential drugs - phase II |
Grantee: | Vanderlan da Silva Bolzani |
Support Opportunities: | BIOTA-FAPESP Program - Thematic Grants |